| |
Veeva Systems today announced that Roche Pharmaceuticals (roche.com) has chosen to extend its partnership with Veeva Systems by adopting Veeva Vault CRM.
“Roche and Veeva have partnered for many years,” said Veeva CEO Peter Gassner. “We are honored to extend our partnership to Vault CRM and bring the next generation of AI-enabled CRM to the global Roche Pharma field teams.”
“We’re excited to expand our partnership with Veeva by implementing Vault CRM across our global Pharma organization,” said Wafaa Mamilli, Roche’s chief digital and technology officer. “With data and AI at its core, Vault CRM will help us create more personalized interactions, giving our teams the insights to better support healthcare professionals and the patients they serve.”
Vault CRM is part of the Vault CRM Suite of applications that provides the foundation for commercial execution. Veeva AI is agentic AI in the Vault platform and deep, industry-specific AI agents in all Veeva applications. Veeva AI Agents for Vault CRM – Free Text Agent, Voice Agent, Pre-call Agent, and Media Agent – are planned for availability in December 2025.
About Veeva Systems
Veeva (veeva.com) delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves.
Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov/.
|
maria.scurry[.]veeva.com 
